UK femcare-turned-gynaecological health startup, Daye, has developed a tampon-based diagnostic kit that tests for sexually transmitted infections (STIs).
The innovative product uses a polymerase chain reaction (PCR) test to check for chlamydia, gonorrhoea, trichomonas, mycoplasma, and ureaplasma.
The tampon is designed to be user-friendly and non-invasive for patients.
Founder of Daye, Valentina Milanova, hopes that the tampon-based at-home STI screening kit will help speed up diagnosis and treatment, particularly among patient groups who are anxious or embarrassed about getting a test.
The product is expected to increase the uptake and accuracy of STI testing, which can be hindered by stigma, patient wait times, and access to care.
According to the UK Health Security Agency, there were over 460,000 diagnoses of sexually transmitted infections in 2020, highlighting the need for convenient and reliable screening methods.
The tampon-based STI screening kit is expected to be a game-changer in the field of gynaecological health, providing a simple and effective solution to an important public health issue.
Daye, a UK-based gynaecological health startup, has created a tampon that can test for sexually transmitted infections (STIs) using a polymerase chain reaction (PCR) test.
This innovative tampon-based STI diagnostic is a convenient, non-invasive, and user-friendly method of screening for five of the most common STIs, including chlamydia, gonorrhoea, trichomonas, mycoplasma, and ureaplasma.
Founded by Valentina Milanova, Daye aims to improve women’s health by providing innovative femcare products.
The STI diagnostic tampon is the latest addition to their product portfolio, which includes a CBD-infused tampon and a repurposed tampon for use as a diagnostic tool.
In an exciting development for the logistics industry, Relay, a London-based startup, has successfully secured a substantial €9.2 million in seed funding. The investment, aimed at transforming the UK’s full-stack delivery network, signifies a considerable vote of confidence from investors…
UK-based tech rental startup Ooodles has recently secured a staggering €11.2 million in funding, marking a significant milestone for the innovative company. Founded in 2021 by industry veteran Leonardo Poggiali,…
London-based Eilla AI has secured €1.4 million in seed funding to transform financial decision-making in private markets. The generative AI platform is designed to assist M&A, venture capital (VC), and…
The development of the STI diagnostic tampon by Daye has the potential to revolutionise STI testing and patient care.
The tampon uses a polymerase chain reaction (PCR) test to check for chlamydia, gonorrhoea, trichomonas, mycoplasma and ureaplasma.
This non-invasive method of testing could increase the uptake and accuracy of STI screening, particularly among patient groups who are anxious or embarrassed about getting a test.
The tampon could also reduce patient wait times and improve access to care. The test failure rate due to insufficient sample collection could be reduced with the tampon, as it simplifies the sample collection process.
The accuracy of the results is also increased due to the tampon’s ability to collect genetic material from pathogens that may be missed by swabs.
The tampon-based STI screening kit could also have implications for cervical cancer and bacterial vaginosis screening.
The tampon collects samples from the cervix and vaginal walls, which could provide insight into the vaginal microbiome and cervical health. This could lead to increased education and research into neglected areas of vaginal physiology.
However, there are also ethical and medical law considerations to be taken into account.
The ownership and analysis of the data collected by the tampon could be a concern for patients.
The consultation process and access to a nurse or medical professional may also be impacted by the simplicity of the tampon-based screening.
Overall, the development of the STI diagnostic tampon by Daye is an exciting development in STI testing and patient care. It has the potential to increase the accuracy and uptake of STI screening, reduce patient wait times, and provide insight into neglected areas of vaginal health.
However, further research and consideration of medical law and ethics is needed to ensure the tampon-based screening is implemented safely and effectively.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.